Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
147.90B
Market cap147.90B
Price-Earnings ratio
19.77
Price-Earnings ratio19.77
Dividend yield
6.67%
Dividend yield6.67%
Average volume
36.90M
Average volume36.90M
High today
$25.96
High today$25.96
Low today
$25.58
Low today$25.58
Open price
$25.75
Open price$25.75
Volume
20.18M
Volume20.18M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$22.81
52 Week low$22.81

Stock Snapshot

The current Pfizer(PFE) stock price is $25.87, with a market capitalization of 147.9B. The stock trades at a price-to-earnings (P/E) ratio of 19.77 and offers a dividend yield of 6.7%.

On 2026-05-21, Pfizer(PFE) stock traded between a low of $25.58 and a high of $25.96. Shares are currently priced at $25.87, which is +1.2% above the low and -0.3% below the high.

The Pfizer(PFE)'s current trading volume is 20.18M, compared to an average daily volume of 36.9M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $22.81.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $22.81.

PFE News

TipRanks 8h
Pfizer: Hold Rating Reiterated as Competitive Pressures Offset Pipeline Upside; $26 Price Target Maintained

Goldman Sachs analyst Asad Haider maintained a Hold rating on Pfizer yesterday and set a price target of $26.00. Meet Samuel – Your Personal Investing Prophet S...

TipRanks 14h
Pfizer Maintained at Buy on Vaccine Franchise Strength and Pipeline Potential; $34 Price Target Reaffirmed

BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer yesterday and set a price target of $34.00. Meet Samuel – Your Personal Investing Prophet S...

Simply Wall St 16h
Is Vaccine And Hematology Progress Reshaping The Investment Case For Pfizer?

Earlier in May 2026, Pfizer reported strong Phase 2 data for its investigational 25‑valent pneumococcal conjugate vaccine in infants and secured a European Comm...

Is Vaccine And Hematology Progress Reshaping The Investment Case For Pfizer?

Analyst ratings

54%

of 28 ratings
Buy
35.7%
Hold
53.6%
Sell
10.7%

More PFE News

Benzinga 2d
Pfizer Expands Pneumococcal Vaccine Push With New Programs

The study showed strong immune responses in infants compared with PREVNAR 20, supporting advancement into Phase 3 testing. Stronger Immune Response Against Ser...

Pfizer Expands Pneumococcal Vaccine Push With New Programs
TipRanks 2d
Notable open interest changes for May 20th

Tuesday’s total option volume of 63.3 million contracts resulted in net open interest growth of 7.39 million calls and 6.34 million puts. Tesla (TSLA), NVIDIA (...

TipRanks 2d
Pfizer announces pneumococcal conjugate vaccine candidate data

Pfizer (PFE) announced data from its Phase 2 study evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent...

Simply Wall St 2d
Pfizer Keeps Oncology Upside As Rigel Takes VEPPANU PROTAC Lead

Pfizer (NYSE:PFE) and Arvinas entered a global license agreement with Rigel Pharmaceuticals to commercialize VEPPANU for advanced or metastatic ER+/HER2- breast...

Pfizer Keeps Oncology Upside As Rigel Takes VEPPANU PROTAC Lead
TipRanks 2d
Pfizer Takes Aim at Merck in New Phase 3 Endometrial Cancer Trial

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

24/7 Wall St. 2d
Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment

Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment By Alex Sirois Published May 19, 10:46AM EDT Quick Read Pfizer (PFE) tr...

Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment
TipRanks 5d
Pfizer Juggles New Trials, Site Shifts and Mixed Wall Street Bets

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Claim 55% Off TipRanks Unlock hedge fund-level data...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.